Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Authors:

Top Cited Papers
Open Access
Abstract
No abstract available
Funding Information
  • Regeneron Pharmaceuticals
  • Sanofi

This publication has 23 references indexed in Scilit: